Atea Pharmaceuticals Announces Upcoming Investor Events
September 07 2022 - 7:00AM
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a
clinical-stage biopharmaceutical company, today announced that Atea
management will participate in the following investor events in
September.
Bemnifosbuvir Global Phase 3 Registrational Trial in
Non-Hospitalized Patients:
- Company management will host a conference call on Tuesday,
September 13, 2022 at 8:30 a.m. ET to provide details on the study
design of the global Phase 3 registrational trial of bemnifosbuvir
and program strategy for the treatment of COVID-19. The event can
be accessed here.
Morgan Stanley 20th Annual Global Healthcare
Conference:
- Jean-Pierre Sommadossi, PhD, Chief Executive Officer and
Founder of Atea, together with members of the Atea management team,
will participate in a fireside chat at the Morgan Stanley 20th
Annual Global Healthcare Conference on Tuesday, September 13, 2022
at 12:55 p.m. ET. The event can be accessed here.
Live webcasts and recordings of these presentations will be
available on the Company’s website at
https://ir.ateapharma.com/news-and-events/events-and-presentations.
About Atea Pharmaceuticals
Atea is a clinical stage biopharmaceutical company focused on
discovering, developing and commercializing oral therapies to
address the unmet medical needs of patients with severe viral
diseases. Leveraging the Company’s deep understanding of antiviral
drug development, nucleos(t)ide chemistry, biology, biochemistry
and virology, Atea has built a proprietary nucleos(t)ide prodrug
platform to develop novel product candidates to treat single
stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent
cause of severe viral diseases. Atea plans to continue to build its
pipeline of antiviral product candidates by augmenting its
nucleos(t)ide platform with other classes of antivirals that may be
used in combination with its nucleos(t)ide product candidates.
Currently, Atea is focused on the development of orally-available
antiviral agents for difficult-to-treat, severe viral infections,
including severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), the virus that causes COVID-19, hepatitis C virus
(HCV), dengue virus and respiratory syncytial virus (RSV). For more
information, please visit www.ateapharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including without limitation statements
regarding our expectations surrounding the potential of our product
candidates, including bemnifosbuvir combination product candidates,
and expectations regarding our pipeline, including trial design and
development timelines. These statements are neither promises nor
guarantees, but involve known and unknown risks, uncertainties and
other important factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements, including, but not limited to, the
uncertainty around and costs associated with the clinical
development of bemnifosbuvir as a potential treatment for COVID-19
and HCV. These and other important factors discussed under the
caption “Risk Factors” in our Annual Report on Form 10-K for the
year ended December 31, 2021 and our other filings with the SEC
could cause actual results to differ materially from those
indicated by the forward-looking statements made in this press
release. Any such forward-looking statements represent management’s
estimates as of the date of this press release. While we may elect
to update such forward-looking statements at some point in the
future, we disclaim any obligation to do so, even if subsequent
events cause our views to change.
Contacts
Jonae BarnesSVP, Investor Relations and Corporate
Communications617-818-2985Barnes.jonae@ateapharma.com
Will O’ConnorStern Investor Relations
212-362-1200will.oconnor@sternir.com
Atea Pharmaceuticals (NASDAQ:AVIR)
Historical Stock Chart
From Jul 2024 to Jul 2024
Atea Pharmaceuticals (NASDAQ:AVIR)
Historical Stock Chart
From Jul 2023 to Jul 2024